In the past week, ADIL stock has gone up by 6.83%, with a monthly decline of -13.70% and a quarterly plunge of -17.24%. The volatility ratio for the week is 6.53%, and the volatility levels for the last 30 days are 8.29% for Adial Pharmaceuticals Inc The simple moving average for the last 20 days is 5.71% for ADIL stock, with a simple moving average of -20.78% for the last 200 days.
Is It Worth Investing in Adial Pharmaceuticals Inc (NASDAQ: ADIL) Right Now?
Moreover, the 36-month beta value for ADIL is 1.13. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ADIL is 6.36M and currently, short sellers hold a 0.95% of that float. On February 25, 2025, ADIL’s average trading volume was 152.83K shares.
ADIL) stock’s latest price update
Adial Pharmaceuticals Inc (NASDAQ: ADIL) has seen a rise in its stock price by 10.35 in relation to its previous close of 0.76. However, the company has experienced a 6.83% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-25 that FDA feedback confirms Adial’s proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval
Analysts’ Opinion of ADIL
Many brokerage firms have already submitted their reports for ADIL stocks, with Rodman & Renshaw repeating the rating for ADIL by listing it as a “Buy.” The predicted price for ADIL in the upcoming period, according to Rodman & Renshaw is $8 based on the research report published on November 14, 2024 of the previous year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see ADIL reach a price target of $5. The rating they have provided for ADIL stocks is “Buy” according to the report published on October 30th, 2018.
ADIL Trading at -10.45% from the 50-Day Moving Average
After a stumble in the market that brought ADIL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.76% of loss for the given period.
Volatility was left at 8.29%, however, over the last 30 days, the volatility rate increased by 6.53%, as shares surge +7.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.57% lower at present.
During the last 5 trading sessions, ADIL rose by +29.07%, which changed the moving average for the period of 200-days by -33.77% in comparison to the 20-day moving average, which settled at $0.8074. In addition, Adial Pharmaceuticals Inc saw -16.42% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ADIL
Current profitability levels for the company are sitting at:
- -252.05 for the present operating margin
- 0.99 for the gross margin
The net margin for Adial Pharmaceuticals Inc stands at -404.61. The total capital return value is set at -1.38. Equity return is now at value -316.95, with -272.04 for asset returns.
Currently, EBITDA for the company is -7.0 million with net debt to EBITDA at 0.63. When we switch over and look at the enterprise to sales, we see a ratio of 5.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.78.
Conclusion
To wrap up, the performance of Adial Pharmaceuticals Inc (ADIL) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
